Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 45 of 60
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

CRISPR, MaxCyte expand partnership into immuno-oncology

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR